A Phase I Study of Tipifarnib Combined With Conventional Induction and Consolidation Therapy for Previously Untreated Patients With Acute Myeloid Leukemia Aged 60 Years and Over

Leukemia - United Kingdom
doi 10.1038/leu.2008.341
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Intensive Consolidation With G-CSF Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy in Acute Myeloid Leukemia Patients ≥60 Years

American Journal of Hematology
Hematology
2017English

Phase II Trial of Clofarabine and Daunorubicin as Induction Therapy for Acute Myeloid Leukemia Patients Greater Than or Equal to 60 Years of Age

Leukemia Research
Cancer ResearchOncologyHematology
2013English

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Renal Replacement Therapy in Patients Aged Over 60 Years.

Postgraduate Medical Journal
Medicine
1987English

Idarubicin, Cytarabine and Pravastatin as Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 With Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy